Analysts Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) Target Price at $751.00

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $751.00.

Several research analysts recently weighed in on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th.

Institutional Investors Weigh In On IDEXX Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SHP Wealth Management purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at $26,000. Elevation Wealth Partners LLC increased its stake in shares of IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the last quarter. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth $29,000. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories during the second quarter valued at $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $544.32 on Wednesday. IDEXX Laboratories has a 52 week low of $518.55 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market capitalization of $42.94 billion, a price-to-earnings ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55. The company has a 50 day moving average price of $556.27 and a 200 day moving average price of $594.80.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts forecast that IDEXX Laboratories will post 14.68 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.